Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

MLA

Johnson, Douglas B., et al. “Neurologic Toxicity Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, Dec. 2019, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s40425-019-0617-x.

APA

Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019). Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. Journal for ImmunoTherapy of Cancer, 7(1), 1–9. https://doi.org/10.1186/s40425-019-0617-x

Chicago

Johnson, Douglas B., Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi, and Joe-Elie Salem. 2019. “Neurologic Toxicity Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study.” Journal for ImmunoTherapy of Cancer 7 (1): 1–9. doi:10.1186/s40425-019-0617-x.